Treatment modalities and survival outcomes in patients with hepatocellular carcinoma with brain metastases (HCC-BM): A large national study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for ...
Response to neoadjuvant immune checkpoint inhibitor (ICI)-based therapy in oncogene-driven resectable non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from the 2023 ASCO Annual ...
In a recent study published in The Lancet Regional Health-Southeast Asia, researchers developed an artificial intelligence (AI)-based predictive system (AIPS) model for the early detection of lung ...
NEWTOWN SQUARE, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of ...
To conclude our interview with Joshua K. Sabari, MD, which focused on the approval of amivantamab plus lazertinib in the first line, he looks ahead to potential uses that could help to overcome ...
In July 2025, the FDA greenlit the use of sunvozertinib (Zegfrovy) for pretreated locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 ...
"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...
Chinese pharma Hansoh Pharma (HKEX: 3692) has secured approval from China’s National Medical Products Administration for an ...
ArriVent BioPharma's furmonertinib demonstrates robust efficacy, CNS penetration, and tolerability in early trials. Read why ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback